TSC2 and lymphangioleiomyomatosis: The combination of RES and rapamycin has been successful in studies on bladder and breast cancer cell lines, lymphangioleiomyomatosis cells, TSC2-deficient cell lines, and TSC2-deficient xenograft tumors in mice [9,146].